Cargando…

Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive cancer linked to asbestos exposure and inhalation. As with other cancers, receiving a diagnosis of MPM is challenging and distressing. Particular challenges are associated with communicating a diagnosis of MPM, including explaining th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Bethany Hope, Warnock, Clare, Tod, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530502/ https://www.ncbi.nlm.nih.gov/pubmed/31179006 http://dx.doi.org/10.1136/bmjresp-2019-000413

Ejemplares similares

Impact of COVID-19 on mesothelioma clinical nurse specialists
por: Taylor, Bethany, et al.
Publicado: (2021)

Patient experiences of participation in a radical thoracic surgical trial: findings from the Mesothelioma and Radical Surgery Trial 2 (MARS 2)
por: Warnock, Clare, et al.
Publicado: (2019)

Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics
por: Gunatilake, Samal, et al.
Publicado: (2021)

Understanding clinical decision-making in mesothelioma care: a mixed methods study
por: Henshall, Catherine, et al.
Publicado: (2022)

Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma
por: Sage, Elizabeth K, et al.
Publicado: (2014)

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
por: Wang, Xiaofei, et al.
Publicado: (2017)

Effects of an Interprofessional Communication Approach on Support Needs, Quality of Life, and Mood of Patients with Advanced Lung Cancer: A Randomized Trial
por: Krug, Katja, et al.
Publicado: (2021)

Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
por: Clive, Amelia O, et al.
Publicado: (2014)

IMPACT OF COVID-19 PANDEMIC ON DIAGNOSIS AND TREATMENT OF LUNG CANCER IN THE VETERAN COHORT
por: ABBAS, HATOON, et al.
Publicado: (2021)

Lifestyle factors and experience of respiratory alarm symptoms in the general population
por: Sele, Lisa Maria Falk, et al.
Publicado: (2015)

A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients
por: Schlachtenberger, G., et al.
Publicado: (2021)

Performance monitoring of EBUS for the staging and diagnosis of lung cancer: auditing the Greater Manchester EBUS service against new national standards
por: Punjabi, Anshu, et al.
Publicado: (2021)

Initial experience with transbronchial cryoablation as a novel local treatment for malignant peripheral lung lesions
por: Kohno, Mitsutomo, et al.
Publicado: (2018)

Cone beam CT-guided navigation bronchoscopy: a cost-effective alternative to CT-guided transthoracic biopsy for diagnosis of peripheral pulmonary nodules
por: Kops, Stephan E P, et al.
Publicado: (2022)

Past and current asbestos exposure and future mesothelioma risks in Britain: The Inhaled Particles Study (TIPS)
por: Gilham, Clare, et al.
Publicado: (2018)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Rehabilitation outcomes for people with lung cancer (UNITE): protocol for the development of a core outcome set
por: Edbrooke, Lara, et al.
Publicado: (2023)

Management of Lung Cancer in the Patient with Interstitial Lung Disease
por: Frank, Angela J, et al.
Publicado: (2022)

Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors
por: Zhang, Lei, et al.
Publicado: (2022)

Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme
por: Lebrett, Mikey B, et al.
Publicado: (2020)

Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
por: Taylor, Sally, et al.
Publicado: (2021)

Feasibility and acceptability of a community pharmacy referral service for suspected lung cancer symptoms
por: Holland-Hart, Daniella, et al.
Publicado: (2021)

Evaluation of cardiovascular risk in a lung cancer screening cohort
por: Ruparel, Mamta, et al.
Publicado: (2019)

What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
por: O'Dowd, Emma L, et al.
Publicado: (2015)

Is investigation of patients with haemoptysis and normal chest radiograph justified?
por: Thirumaran, M, et al.
Publicado: (2009)

Prevalence and outcome of central airway obstruction in patients with lung cancer
por: Daneshvar, Cyrus, et al.
Publicado: (2019)

Diffuse Alveolar Hemorrhage in a Patient Receiving Bevacizumab for Lung Cancer
por: Sethi, Sakshi, et al.
Publicado: (2014)

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
por: Møller, Henrik, et al.
Publicado: (2018)

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review
por: Xiong, Wei, et al.
Publicado: (2023)

Integrated care for resected early stage lung cancer: innovations and exploring patient needs
por: Ho, Jan, et al.
Publicado: (2017)

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
por: Lüchtenborg, Margreet, et al.
Publicado: (2014)

Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
por: Lok, Benjamin H., et al.
Publicado: (2017)

PRIMARY PULMONARY CAVITATING ADENOCARCINOMA IN A PATIENT PRESENTING WITH COVID-19 PNEUMONIA: A CASE REPORT
por: TIJANI, SULAIMAN, et al.
Publicado: (2022)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
por: Lemmon, Christopher A, et al.
Publicado: (2022)

Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer
por: Lüchtenborg, Margreet, et al.
Publicado: (2018)

White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer
por: Sibille, A., et al.
Publicado: (2021)

A RARE PRESENTATION OF PRIMARY LUNG ADENOCARCINOMA PRESENTING WITH PERICARDIAL EFFUSION AND TAMPONADE IN A COVID-19 POSITIVE PATIENT
por: FOLARANMI, OLUFUNMILAYO, et al.
Publicado: (2021)

Factors leading to the risk of stroke mortality: a cross-sectional study with lung cancer patient-based large sample
por: Chen, Lei, et al.
Publicado: (2021)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ecgthkqfeusjvi4vbj0cehu0k